Seeking Alpha
 

Heron Therapeutics, Inc. (HRTX)

- NASDAQ
  • Celera1 | Send Message 1 Mar

    $HRTX: High-Tech delivery platform - Top-Management - Strong Pipeline - Huge market opportunities - 2015 Game-changing Year.
    Reply
      • Celera1 | Send Message 1 Mar

        Is the future of pharma about making good drugs great? Yes, and $HRTX makes existing drugs much better. http://for.tn/18A0DsX
        Reply
          • Celera1 | Send Message 1 Mar

            Fortune.com about $HRTX: Heron Therapeutic's HRTX high-tech Biochronomer platform makes existing injectable drugs longer lasting.
            Reply
              • Celera1 | Send Message 19 Feb

                $HRTX drug HTX-011 is significantly superior to EXPAREL. Pacira Pharma expects $59.0 million in net revenue for EXPAREL in 4Q2014.
                Reply
                  • Celera1 | Send Message 19 Feb

                    Heron Therapeutics $HRTX Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain
                    Reply (2)
                    • matratra | Send Message 19 Feb
                      : There are lots of other including ZGNX.
                    • Celera1 | Send Message 19 Feb
                      : HTX-011 is a long acting bupivacaine and significantly reduced pain through 72 hours. Superior to very successful market drug EXPAREL.
                      • Celera1 | Send Message 9 Feb

                        $HRTX Results of Phase3 MAGIC Study in 1Q2015. Presentation at Leerink Partner Conference on Wednesday, February 11, 2015.
                        Reply
                          • Celera1 | Send Message 16 Jan

                            $HRTX Medical Officer M.S.Gelder resigns.He was hired 2012-before the latest Complete Response Letter. Think the new CMO will be a surprise!
                            Reply
                              • Celera1 | Send Message 13 Jan

                                In addition to SUSTOL $HRTX expect rapid development of HTX-019 - an NK1 receptor antagonist with anticipated NDA Submission 1H2016.
                                Reply
                                  • Celera1 | Send Message 13 Jan

                                    $HRTX HEC-Study expect to complete in 1Q2015. Resubmission is looming!
                                    Reply
                                      • Celera1 | Send Message 13 Jan

                                        $HRTX: Higher proportion of patients are evaluable than initially projected, so fewer randomized patients will be needed to achieve target.
                                        Reply
                                          Visit Seeking Alpha's
                                          HRTX vs. ETF Alternatives
                                          Company Description
                                          Heron Therapeutics Incis a biotechnology company, developing products to address unmet medical needs. ItsproprietaryBiochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.